A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1. Subjects with active central nervous system metastases or meningeal metastases;
• •2. History of serious cardiovascular and cerebrovascular diseases;
• •3. Subjects with a history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis;
• •4. Severe infection within 4 weeks prior to the first dose;
• •5. Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of study drug;
• •6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.